[go: up one dir, main page]

MX377774B - Formulaciones de proteinas. - Google Patents

Formulaciones de proteinas.

Info

Publication number
MX377774B
MX377774B MX2016017025A MX2016017025A MX377774B MX 377774 B MX377774 B MX 377774B MX 2016017025 A MX2016017025 A MX 2016017025A MX 2016017025 A MX2016017025 A MX 2016017025A MX 377774 B MX377774 B MX 377774B
Authority
MX
Mexico
Prior art keywords
protein formulations
formulations
present disclosure
temperatures
variety
Prior art date
Application number
MX2016017025A
Other languages
English (en)
Other versions
MX2016017025A (es
Inventor
Arnold J Mcauley
Sungae Park
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016017025A publication Critical patent/MX2016017025A/es
Publication of MX377774B publication Critical patent/MX377774B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a formulaciones sólidas de proteínas que son estables sobre una variedad de temperaturas durante períodos prolongados de tiempo. La presente descripción también proporciona los métodos para preparar y utilizar estas formulaciones.
MX2016017025A 2014-06-26 2015-06-15 Formulaciones de proteinas. MX377774B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017560P 2014-06-26 2014-06-26
PCT/US2015/035884 WO2015200027A1 (en) 2014-06-26 2015-06-15 Protein formulations

Publications (2)

Publication Number Publication Date
MX2016017025A MX2016017025A (es) 2017-08-08
MX377774B true MX377774B (es) 2025-03-11

Family

ID=53610976

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016017025A MX377774B (es) 2014-06-26 2015-06-15 Formulaciones de proteinas.
MX2020012893A MX2020012893A (es) 2014-06-26 2016-12-19 Formulaciones de proteinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012893A MX2020012893A (es) 2014-06-26 2016-12-19 Formulaciones de proteinas.

Country Status (8)

Country Link
US (1) US20170209582A1 (es)
EP (2) EP3160511B1 (es)
JP (5) JP6634394B2 (es)
AU (3) AU2015280480A1 (es)
CA (1) CA2952609A1 (es)
ES (1) ES2960599T3 (es)
MX (2) MX377774B (es)
WO (1) WO2015200027A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101994456B1 (ko) * 2017-03-15 2019-06-28 이건무 당 수액제 조성물
CN120884714A (zh) * 2017-11-16 2025-11-04 美国安进公司 聚乙二醇化卡非佐米化合物的稳定的组合物
CN118948760A (zh) 2018-05-10 2024-11-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
JP2023512446A (ja) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物
US20230357432A1 (en) * 2020-09-24 2023-11-09 Novo Nordisk Health A/S Pharmaceutical formulation of concizumab and method of production thereof
KR20230121797A (ko) * 2020-12-17 2023-08-21 아스트라제네카 아베 항-il5r 항체 제형
EP4642233A1 (en) 2022-12-30 2025-11-05 Biotalys NV Agglomerate
WO2025013783A1 (ja) * 2023-07-07 2025-01-16 ナガセヴィータ株式会社 タンパク質の変性抑制用組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN102416176A (zh) * 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE60235013D1 (de) * 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
ES2390354T3 (es) * 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
MX2009003982A (es) * 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
JP5819303B2 (ja) * 2009-09-21 2015-11-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2013169734A1 (en) 2012-05-07 2013-11-14 Amgen Inc. Anti-erythropoietin antibodies

Also Published As

Publication number Publication date
JP2025160348A (ja) 2025-10-22
JP6634394B2 (ja) 2020-01-22
JP2023162442A (ja) 2023-11-08
EP3160511B1 (en) 2023-07-26
AU2023200296A1 (en) 2023-02-23
EP4285930A2 (en) 2023-12-06
ES2960599T3 (es) 2024-03-05
AU2020250182A1 (en) 2020-11-05
JP2017519777A (ja) 2017-07-20
US20170209582A1 (en) 2017-07-27
MX2016017025A (es) 2017-08-08
AU2015280480A1 (en) 2017-01-05
CA2952609A1 (en) 2015-12-30
JP2019203018A (ja) 2019-11-28
JP2021178862A (ja) 2021-11-18
AU2023200296B2 (en) 2024-09-19
EP4285930A3 (en) 2024-02-28
WO2015200027A1 (en) 2015-12-30
EP3160511A1 (en) 2017-05-03
MX2020012893A (es) 2021-02-26

Similar Documents

Publication Publication Date Title
IL282372A (en) Haploid induction compositions and methods for use therefor
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112019012342A2 (pt) anticorpos il-11
IL248519A0 (en) Bioceramic compositions and biomodulatory uses thereof
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
CL2016001871A1 (es) Anticuerpos humanos para pd-1
DK3104718T3 (da) Tobaksholdig gelsammensætning
GEAP202114450A (en) Anti-tigit antibodies
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX377774B (es) Formulaciones de proteinas.
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
DK3630968T3 (da) Enzymer til glycananalyse
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EP3562837A4 (en) MODIFIED LYSINE DECARBOXYLASE ENZYMES
IL252191A0 (en) Compositions and methods for modulating at2r activity
EA201691203A1 (ru) Твёрдые формы тенофовира
EP3432728C0 (en) ENZYMATIC COMPOSITIONS
EP3679373A4 (en) IMPROVED IMMUNOTHERAPY
NZ744340A (en) Anti-jagged1 antibodies and methods of use
CL2015002917S1 (es) Mazo dental

Legal Events

Date Code Title Description
FG Grant or registration